Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN

Recruiting now

Conditions studied: HPV Infection, Cervical Cancer

In brief

This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old. This follow-up is proposed as an alternative to the treatment of reference (conization) with a possible extension to 4 years

Key facts

Study ID

NCT04057924

Run by

University Hospital, Bordeaux

People needed

200

Starts

2019-08-23

Expected to finish

2029-09-01

Last updated by the study team

2025-02-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• CIN2 confirmed by biopsy, age between 18 and 39 years,
• satisfactory colposcopy identifying the junction and the lesion,
• affiliated person or beneficiary of a social security scheme,
• having given their oral agreement and authorization to the processing of their data.

You may not qualify if…

• Pregnancy in progress,
• history of conization,
• atypical or atypical glandular cells or cancer incidentally discovered during smear,
• prophylactic vaccination against HPV,
• active systemic infection requiring treatment, history of HIV infection, congenital or acquired immunodepression,
• long-term treatment with corticosteroids or immunosuppressants, placement under safeguard of justice,
• non-compliance with protocol requirements, in particular a supposed lack of compliance with long-term follow-up

Where it is running

• CHU Bordeaux — Bordeaux, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.